Use of Acetyl Salicylic Acid and Terbutalin in Assisted Reproductive Techniques (ART)

This study has been completed.

Sponsor:

Information provided by:

Sykehuset Telemark

ClinicalTrials.gov Identifier:

NCT00518141

First received: August 17, 2007

Last updated: July 20, 2011

Last verified: July 2011

History of Changes

Purpose

This study aims to determine the possible effects of Acetyl Salicylic Acid (ASA) and Terbutalin on ART treatment.

Condition	Intervention
Reproductive Techniques, Assisted	Drug: Acetyl Salicylic Acid and Terbutalin


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Use of Acetylsalicylic Acid and Terbutalin in ART

Resource links provided by NLM:

MedlinePlus related topics: Assisted Reproductive Technology

Drug Information available for: Aspirin Salicylic acid

U.S. FDA Resources

Further study details as provided by Sykehuset Telemark:

Primary Outcome Measures:

Pregnancy [ Time Frame: 7 weeks ] [ Designated as safety issue: No ]


Enrollment:	300
Study Start Date:	March 2006
Study Completion Date:	May 2009
Primary Completion Date:	May 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1 FER	Drug: Acetyl Salicylic Acid and Terbutalin ASA 75 mg, Terbutalin 5mg
No Intervention: 2 FER
Experimental: 3 SET	Drug: Acetyl Salicylic Acid and Terbutalin ASA 75 mg, Terbutalin 5mg
No Intervention: 4 SET
Experimental: 5 DET	Drug: Acetyl Salicylic Acid and Terbutalin ASA 75 mg, Terbutalin 5mg
No Intervention: 6 DET

Detailed Description:

This study aims to determine the possible effects of ASA and Terbutalin on ART treatment.

Eligibility


Ages Eligible for Study:	18 Years to 39 Years (Adult)
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Infertile women below 39 years of age

Exclusion Criteria:

Women who may react allergically to the drugs administered
Women with hyperthyroid or IDDM
Women who do not want to participate in the study
Women who are unable to give informed, written consent.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00518141

Locations


Norway
STHF, Kvinneklinikken, Fertilitetsklinikken Sor
Porsgrunn, Telemark, Norway, 3901

Sponsors and Collaborators

Sykehuset Telemark

Investigators


Principal Investigator:	Jarl A Kahn, Dr. med	STHF, Kvinneklinikken, Fertilitetsklinikken Sor

More Information


Responsible Party:	Jarl Kahn, Fertilitetsklinikken Sør
ClinicalTrials.gov Identifier:	NCT00518141 History of Changes
Other Study ID Numbers:	S-06085 (REK)
Study First Received:	August 17, 2007
Last Updated:	July 20, 2011
Health Authority:	Norway:National Committee for Medical and Health Research Ethics

Additional relevant MeSH terms:


Aspirin Salicylates Salicylic Acid Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents	Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Platelet Aggregation Inhibitors Cyclooxygenase Inhibitors Enzyme Inhibitors Antipyretics Anti-Infective Agents Antifungal Agents Keratolytic Agents Dermatologic Agents

ClinicalTrials.gov processed this record on September 23, 2016

To Top